Mild cognitive impairment, or MCI, is a stage of cognitive decline that goes beyond normal age-related forgetfulness but doesn’t interfere with your ability to live independently. About 23.7% of adults over 65 have it, making it remarkably common. MCI is not dementia, and not everyone who has it will develop dementia, but it does increase the risk.
How MCI Differs From Normal Aging
Everyone’s brain slows down with age. It takes longer to recall a name or find the right word, and that’s perfectly normal. MCI is different in degree. Where normal aging might mean occasionally blanking on an acquaintance’s name, MCI means forgetting things more often and more noticeably, including important appointments or social events. You might lose the thread of a conversation, struggle to follow the plot of a movie, or repeatedly search for common words in a way that people around you begin to notice.
The key distinction is that with MCI, someone close to you, or you yourself, can tell something has changed. A clinician can also measure it on cognitive testing. But you’re still paying your bills, driving, cooking, and managing daily life without needing help. Once those everyday abilities start breaking down, the diagnosis shifts toward dementia.
The Two Main Types
MCI comes in two broad forms depending on which mental abilities are affected. Amnestic MCI primarily hits memory. People with this type have measurably worse performance on tests of learning and recalling new information compared to both healthy adults and those with the other type. They also tend to struggle more with naming items in categories (like listing as many animals as possible in a minute). Amnestic MCI is more closely linked to Alzheimer’s disease.
Non-amnestic MCI leaves memory relatively intact but affects other thinking skills. People with this type show more difficulty with tasks like generating words that start with a specific letter, a skill tied to language processing and mental flexibility. Both types show reduced performance on tasks requiring attention and mental switching, which reflects changes in the brain’s frontal regions. Non-amnestic MCI is sometimes associated with other forms of dementia, such as vascular dementia or Lewy body disease, though this isn’t always the case.
How It’s Diagnosed
There’s no single blood test or brain scan that confirms MCI. Diagnosis relies on four core criteria: a cognitive concern raised by you, someone who knows you well, or a clinician; measurable impairment on neuropsychological testing; essentially normal ability to handle daily activities; and the absence of dementia.
One widely used screening tool is the Montreal Cognitive Assessment (MoCA), a brief test covering memory, attention, language, and other domains. Scores of 25 to 30 are generally considered normal, while scores of 20 to 24 suggest mild impairment. The original test developers define scores between 18 and 25 as mild impairment, so there’s some variability in how cutoffs are applied.
Beyond cognitive testing, doctors run blood work to check for treatable conditions that could be causing the symptoms. This typically includes thyroid function, vitamin B12 levels, blood sugar, kidney function, and a complete blood count. A thorough medication review is also standard, since many common drugs can fog thinking.
Reversible Causes That Mimic MCI
Not all cognitive decline is permanent, and one of the most important parts of an evaluation is ruling out fixable problems. Hypothyroidism, vitamin B12 deficiency, dehydration, blood sugar imbalances (too high or too low), and even urinary tract infections can all cause cognitive symptoms that look like MCI but resolve with treatment.
Medications are a major and underappreciated culprit. Sleep aids, anti-anxiety medications like benzodiazepines, muscle relaxants, seizure drugs, opioids, and a broad class called anticholinergics (which includes certain antihistamines, antidepressants, bladder medications, and antipsychotics) can all impair memory. Blood pressure medications that cause dizziness from standing up too quickly can also affect cognition. Drug interactions between multiple medications compound the problem. The good news is that medication-related cognitive decline is reversible once the offending drugs are identified and adjusted.
Depression, obstructive sleep apnea, and vitamin deficiencies are other treatable conditions that should be addressed before assuming cognitive decline is permanent.
Does MCI Always Lead to Dementia?
No. MCI is not a guaranteed stepping stone to Alzheimer’s or other dementias. In longitudinal studies, the average annual conversion rate from MCI to dementia is roughly 10 to 15%. That means in any given year, the large majority of people with MCI do not progress. Some remain stable for years, and a meaningful proportion actually revert to normal cognition. In one study tracking patients over several years, about 24% of those diagnosed with MCI were reclassified as cognitively normal at later follow-up points.
Certain biological markers do help predict who is more likely to progress. In people with MCI, the buildup of amyloid protein (the sticky plaques associated with Alzheimer’s) in the brain tends to have already leveled off, but levels of tau protein, which is linked to nerve cell damage, continue to climb. Higher tau levels in people with MCI are associated with faster cognitive decline over time. These markers can be measured through spinal fluid tests or specialized brain imaging, though such testing is not routine and is mainly used in research settings or when considering newer treatments.
Treatment Options
For years, there was no effective drug treatment for MCI. Older dementia medications like cholinesterase inhibitors were tested extensively in MCI patients across trials lasting one to four years, and none showed significant benefit. These drugs were never approved for MCI.
That changed in 2023 and 2024 with the approval of two anti-amyloid immunotherapies: lecanemab (approved 2023) and donanemab (approved 2024). Both are specifically indicated for early-stage Alzheimer’s disease, a category that includes MCI when it’s caused by Alzheimer’s pathology. In clinical trials, roughly 65 to 80% of participants were at the MCI stage rather than the mild dementia stage, so the evidence base is strongest for this group. These treatments work by clearing amyloid plaques from the brain and have been shown to slow the rate of cognitive decline.
There’s an important catch: eligibility requires confirmation that Alzheimer’s pathology is actually present, through either an amyloid PET brain scan or spinal fluid testing showing abnormal amyloid and tau levels. MCI caused by other factors wouldn’t qualify, and the treatments carry risks including brain swelling and small brain bleeds that require regular monitoring with MRI.
Lifestyle Factors That Matter
Physical exercise is one of the most consistently supported interventions for people with MCI. In one study examining lifestyle influences on MCI progression, people who exercised regularly had a substantially lower rate of worsening: about 43% progressed compared to over 72% of those who were sedentary and had no regular hobbies. That’s a striking difference, even accounting for other variables.
Beyond exercise, the factors that support brain health in MCI are largely the same ones that protect cardiovascular health: staying socially engaged, managing blood pressure and blood sugar, maintaining a healthy weight, getting adequate sleep, and treating depression or sleep apnea if present. Cognitive engagement through hobbies, learning new skills, or social activities also appears protective, though the evidence is stronger for physical activity than for any single mental exercise program.
The practical takeaway is that MCI is a diagnosis with real variability in outcomes. Some people worsen, many stay the same, and some improve, particularly when reversible causes are identified and addressed. It’s a signal to pay attention, get a thorough evaluation, and focus on the modifiable factors that can shift the odds.